Author: Admin

Developer

Release – Schwazze Signs Definitive Agreement to Acquire Drift

Posted on by Admin


Schwazze Signs Definitive Agreement to Acquire Drift

 

Acquisition Expands Retail Footprint in Boulder County, Colorado

DENVER, CO – June 29, 2021 – Schwazze, (OTCQX:SHWZ) (“Schwazze” or the “Company”), announced signed definitive documents to acquire the assets of BG3 Investments, LLC dba Drift which consists of two marijuana retail stores located in Boulder, Colorado. This purchase continues Schwazze’s expansion and growth plans in Colorado adding to the Company’s current dispensary footprint, with nine dispensaries acquired year to date, bringing the total number of dispensaries to nineteen. As part of the purchase, Schwazze will also acquire the assets of Black Box Licensing, LLC, which contains certain intellectual property.

“We look forward to adding these dispensaries to our portfolio. The Company remains focused on bringing excellent customer experiences to all areas of Colorado, and we are excited to bring that experience to our customers in Boulder,” said Justin Dye, Schwazze’s CEO.

The consideration for the proposed acquisition is $3.5 million and will be paid as $1.9 million in cash, and $1.6 million in common stock. This transaction represents a 3.5 times multiple based on the projected 2021 adjusted EBITDA for the two dispensaries. The acquisition is expected to close during the third quarter of 2021 after the Colorado Marijuana Enforcement Division and local licensing approval.

About Schwazze
Schwazze (OTCQX: SHWZ) is the parent company of a portfolio of vertically integrated cannabis brands spanning seed to sale. The company’s intent is to apply its operational playbook by expanding into markets where it can entrench itself in a leadership position. Anchored by a high-performance culture, Schwazze focuses on growth by purposeful design, combining customer-centric thinking and data science to test, measure, and drive desired outcomes. The company’s leadership team has deep expertise in CPG, retail, and building consumer brands at Fortune 500 companies as well as in the cannabis sector. Schwazze is passionate about improving the human condition; making a difference in our communities; promoting diversity and inclusion; and focusing on sustainable best practices.

Schwazze derives its name from the pruning technique of a cannabis plant to promote growth. Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc.

Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “may,” “estimates”, “predicts,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; (v) difficulties in securing regulatory approval to market our products and product candidates; (vi) our ability to successfully execute our growth strategy in Colorado and outside the state, (vii) our ability to identify and consummate future acquisitions that meet our criteria, (viii) our ability to successfully integrate acquired businesses and realize synergies therefrom, (ix) the actual revenues derived from the Company’s Star Buds assets, (x) the Company’s actual revenue and adjusted EBITDA for 2021, (xi) the Company’s ability to generate positive cash flow for the rest of 2021 (xii) the ongoing COVID-19 pandemic, (xiii) the timing and extent of governmental stimulus programs, and (xiv) the uncertainty in the application of federal, state and local laws to our business, and any changes in such laws. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investors
Joanne Jobin
Investor Relations
[email protected]
647 964 0292

Media
Julie Suntrup, Schwazze
Vice President | Marketing & Merchandising
[email protected]
303 371 0387

Golden Predator Mining (NTGSF)(GPY:CA) – Arizona Gold Corp. Golden Predator Sabre Gold Corp.

Posted on by Admin

Tuesday, June 29, 2021

Golden Predator Mining (NTGSF)(GPY:CA)
Arizona Gold Corp. + Golden Predator = Sabre Gold Corp.

Golden Predator Mining Corp is a Canada based exploration stage company engaged in the business of acquiring and exploring mineral properties. It owns properties primarily in Yukon, Canada. Some of the company’s projects located in Yukon are the 3 Aces, Sprogge, Reef, Brewery Creek, Marg, Sonora Gulch, Grew Creek, Upper Hyland and others.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Arizona Gold Corp. to acquire Golden Predator. Arizona Gold Corp. (TSX: AZG, OTCQB: AGAUF) and Golden Predator announced an agreement to merge and create a new North American focused near-term gold producer in an all-stock transaction. The deal, expected to close in September 2021, combines the fully permitted past producing Copperstone gold mine in Arizona and the past producing Brewery Creek gold mine in the Yukon. Shareholders of Golden Predator will receive 1.65 common shares of Arizona Gold Corp. for each share of Golden Predator. Upon closing, Arizona Gold is expected to change its name to Sabre Gold Corp. The companies will host an investor webinar on June 29 at 1:00 pm ET.

    Transaction benefits.  Benefits include: 1) greater size and diversification, 2) a combined 175 thousand ounces of proven and probable gold reserves, measured and indicated resources of 1.1 million ounces of gold, 1.5 million ounces of gold in the inferred category, along with significant exploration potential, 3) a strong balance sheet with combined cash and investments amounting to C$23.0 million …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

FAT Brands Inc. (FAT) – A New Paradigm Acquiring Global Franchise Group

Posted on by Admin

Tuesday, June 29, 2021

FAT Brands Inc. (FAT)
A New Paradigm: Acquiring Global Franchise Group

FAT Brands Inc is a multi-brand restaurant franchising company. It develops, markets, and acquires predominantly fast casual restaurant concepts. The company provides turkey burgers, chicken Sandwiches, chicken tenders, burgers, ribs, wrap sandwiches, and others. Its brand portfolio comprises Fatburger, Buffalo’s Cafe and Express, and Ponderosa and Bonanza. The company’s overall footprint covers nearly 32 countries. Fatburger generates maximum revenue for the company.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Acquisition. Yesterday, FAT Brands announced the acquisition of Global Franchise Group for $442.5 million in cash and stock. With the acquisition, FAT Brands will have more than 2,000 franchised and company-owned restaurants around the world, with combined annual system-wide sales of approximately $1.4 billion. On a normalized basis, FAT Brands should generate about $100 million of annual revenue and $60 million of EBITDA.

    Who Is Global Franchise Group? Previously owned by Serruya Private Equity and Lion Capital, GFG is a strategic brand management company operating more than 1,400 locations across five quick service restaurant concepts in 16 countries.  The concepts are Round Table Pizza, Great American Cookies, Hot Dog on a Stick, Marble Slab Creamery, and Pretzelmaker …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Digerati Technologies Inc. (DTGI) – Elbowing Into An Attractive Niche

Posted on by Admin

Tuesday, June 29, 2021

Digerati Technologies, Inc. (DTGI)
Elbowing Into An Attractive Niche

Digerati Technologies, Inc. (OTCQB: DTGI) is a telecom and technology provider of diverse, carrier-grade, Only in the Cloud™ communication and network solutions including Unified Communication as a Service, cloud telephony, cloud WAN, cloud call center, cloud mobile, and delivery of digital oxygen on its fiber/mobile broadband network. Digerati has developed a robust integration platform to fuel mergers and acquisitions in a highly fragmented market as it delivers flexible, cost-effective services with enterprise-grade quality and reliability. A multi-year recipient of Deloitte’s Fast500 and Fast50 Awards for one of the fastest growing technology companies in North America, Digerati has become an expert at successfully merging and managing subsidiary operations since 2015. The Company’s impressive tech-stack serves 28,000 business users on its platform and its dynamic channel program includes over 300 channel partners that serve as a conduit for sales growth. Digerati has continuously increased customer adoption while serving diverse industries including Healthcare, Banking, Financial Services, Legal, Real Estate, and Construction. Digerati currently has a strong platform for growth throughout Texas and Florida, the 2nd and 4th largest state economies by GDP in the U.S. The Company’s clean and clear fundamentals, combined with its clearly defined growth plan, disciplined acquisition strategy and seasoned leadership team is expected to increase shareholder value as it enters the next phase of its corporate development plan. For more information, please visit www.digerati-inc.com.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Initiating coverage. We believe that there is more to this story than a simple roll-up strategy of attractive, small to medium sized, cloud based telecommunication companies. There are dynamic, organic growth opportunities given favorable industry trends, its focus on high growth markets and its local support that differentiates itself from larger, national industry players.

    Attractive growth markets/High recurring revenue.  Current operations are in high growth markets of Texas and Florida. In addition, the business has very low churn rates of roughly 0.3% to 1%, which is less than industry averages of 1% to 2%. Finally, 95% of the company’s revenue is under long term contracts of 1 to 5 years, with the average of 3 years …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Onconova Therapeutics Provides An Update On The Phase 1/2a Trial Of Rigosertib-Nivolumab Combination In KRAS+ Non-Small Cell Lung Cancer

Posted on by Admin


Onconova Therapeutics Provides An Update On The Phase 1/2a Trial Of Rigosertib-Nivolumab Combination In KRAS+ Non-Small Cell Lung Cancer

 

Expansion of trial underway at highest dose in the current protocol, and continued dose escalation under consideration

Preliminary data support the preclinical observation of rigosertib augmenting the response to immune checkpoint inhibition

NEWTOWN, Pa., June 28, 2021 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced an update on the investigator-initiated Phase 1/2a trial of oral rigosertib plus nivolumab in advanced metastatic KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC). The clinical data to date provide preliminary evidence of potential anti-cancer activity of rigosertib-nivolumab combination therapy in advanced metastatic KRAS+ non-small cell lung cancer and show that the maximum tolerated dose of rigosertib in combination with nivolumab was not reached in the three cohorts of the trial’s dose-escalation phase. Patients enrolled in this trial have failed multiple lines of prior therapy and all have failed immune checkpoint inhibitors in various combinations.

The trial continues to recruit patients as part of the expansion phase at the highest dose of oral rigosertib defined in the current protocol. Based on the positive preliminary findings from the trial, a protocol amendment is being prepared that would allow for the evaluation of increased rigosertib doses in combination with the full dose of intravenous nivolumab, as recommended per its product label.

“The preliminary results from this Phase 1/2a trial are very encouraging and demonstrate the potential of rigosertib to address a critical unmet medical need by overcoming checkpoint inhibitor resistance in KRAS mutated lung adenocarcinoma,” said Mark S. Gelder, M.D., Chief Medical Officer of Onconova. “The observation of preliminary evidence of efficacy in combination with acceptable safety of the doublet in this extremely challenging patient population provides a promising signal. This phase 1 study supports the preclinical observation in melanoma of the up regulation of crucial cell surface molecules by rigosertib which may synergize with immune checkpoint blockade, as recently published in Molecular Cancer, and strongly supports the continued clinical development of rigosertib-checkpoint inhibitor combination therapy. We look forward to the presentation of preliminary data at the upcoming 3rd Annual RAS Targeted Drug Development Summit taking place September 21-23, 2021, and at a future major medical meeting as the data mature.”

Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, commented, “This Phase 1/2a trial is an important part of our investigator-initiated study program, which enables us to pursue opportunities to develop rigosertib in high-need KRAS mutated indications while maintaining our primary focus on our lead ON 123300 program. We are very pleased both with the safety and preliminary efficacy signal we have seen from the KRAS mutated NSCLC trial to date, considering the multiple lines of therapy many of these patients have previously failed, including checkpoint inhibitors in various combinations. We are supportive of the plan to expand dose-escalation of rigosertib to determine the optimal recommended Phase 2 dose of the combination; and are eagerly anticipating results of important correlative science that is part of the trial. We look forward to the trial’s continued progress and would like to thank the investigator and his team for conducting the trial, as well as the patients who are participating.”

About the Investigator-initiated Phase 1/2a Trial
This Phase 1/2a trial is designed to evaluate the combination of rigosertib and nivolumab in advanced KRAS+ metastatic lung adenocarcinoma patients who have progressed on standard of care with anti-PD-1 monotherapy or anti-PD-1 in combination with chemotherapy. It includes a dose-escalating Phase 1 portion followed by a Phase 2a dose-expansion portion. Patients in the trial receive oral rigosertib twice daily on days 1-21, and intravenous nivolumab on days 1 and 15 of 28-day cycles. The primary endpoints of the trial are safety assessments and overall response rate. Secondary endpoints include progression free survival and overall survival. For more information on the trial, see ClinicalTrials.gov Identifier: NCT04263090.

About Onconova Therapeutics, Inc.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, including in a dose-escalation and expansion Phase 1/2a investigator-initiated study targeting patients with KRAS+ non-small cell lung cancer with oral rigosertib in combination with nivolumab. In addition, Onconova continues to conduct preclinical work investigating rigosertib in COVID-19.

For more information, please visit www.onconova.com.

Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the timing of Onconova’s and investigator-initiated clinical development and data presentation plans, and the mechanisms and indications for Onconova’s product candidates. Onconova has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova’s clinical trials, investigator-initiated trials and regulatory agency and institutional review board approvals of protocols, Onconova’s collaborations, the timing of the Company’s annual stockholder meeting, market conditions and those discussed under the heading “Risk Factors” in Onconova’s most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
[email protected]
https://www.onconova.com/contact/

Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
[email protected]

The High Growth of ESG Investing can Reduce Adherence to Principles

Posted on by Admin 

Image Credit: Pixabay (Pexels)


ESG Investors Who are Concerned About Environmental and Social Impact Should Closely Watch Their Investments

 

ESG funds received double the amount of money in 2020 than they did in 2021. Funds that say they use ESG principles or Environmental, Social, and Governance to dictate their investment universe captured $51.1 billion in net new money from investors in 2020. This is the fifth year in a row this subset of funds has set a record on higher net increases.

Since the start of 2019, stock mutual funds and stock ETFs with ESG as part of their selection process have received a net $473 billion from investors. To illustrate how big this is, only $103 billion has gone into all other stock funds. With all this new money entering ESG funds, some companies are inclined to “paint themselves as green” in order to get investor attention. Some fund managers flush with new cash may be inclined to stretch their definition in order to keep fully invested.

Two Types of ESG Investors

There are two primary types of ESG investors, those that are very concerned for the environment and hold certain social beliefs dear, and there are those that want to ride the wave of a trend that has a great deal of money chasing it. For those trying to capture a trend, ETFs and mutual funds geared toward this label may make sense. For investors truly concerned about the environment, and would like to be more sure companies they own behave in ways they deem important, they may wish to create their own portfolio. In this way, they can be more intimate with each company they decide to own.

Funds “Cheat”

 In 1990 the mutual fund company I worked for opened one of the first social choice accounts. The idea was that it would support investments that “did good” and shun those that caused harm. Many of the environmental guidelines are similar to todays’ ESG funds; back then, we also eliminated any investments related to apartheid South Africa and required adherence to the MacBride Principles in Northern Ireland. As I recall, we screened to make sure there were no tobacco, alcohol, or firearms related companies. As a new fund, it was seeded with a $200 million investment from an existing large fund we managed. When a new fund is seeded, before investors arrive, the investments are kept somewhat liquid and low risk as the money needs to be returned to the sister fund.  My role was to invest this money, initially, it was expected to be placed in U.S. Treasury Notes. The problem I had with this is I read the prospectus, and within it was language that suggested that issuers that produced or were in the business of funding firearms were to be excluded. Certainly, the U.S. Treasury as an issuer fell into this category.  Long story short, we made an exception—one of many exceptions we made for that fund over the years.  With little competition for suitable companies, we broke our own social guidance on day one.

Companies “Cheat”

 A story in this past Friday’s Wall
Street Journal highlighted an entrepreneur whose company, which mined the sea floor, went broke as the local government cracked down on his mining of the sensitive seabed.  The same entrepreneur has recently gotten back into the business of seabed mining, but this time positioning his new seabed mining venture, The Metals Company (TMS), as green, to attract capital during this surge of environmentally steered funds.

TMC is likely to receive approximately $600 million in investor cash in a deal to take the company public in July. If successful, that would value TMC at $2.9 billion—more than any mining company ever to go public in the U.S. with no revenue.

This is one example where a company that produces something for one green industry may not produce it in a way that would make environmentally-minded people comfortable. But fitting an ESG definition at times is all that is needed to attract capital from large managers.

Alternative to Funds

Investors that are drawn to this category, particularly with the demands placed on fund managers inundated with cash and searching for value in trading-lot sizes of $1 million or more, may want to rely on their own evaluations. Technology has changed and makes this easier and more cost-efficient than ever before. We are lucky to have a trading environment where transactions are essentially free, fractional shares are available at many brokers, and access to company information is at your computer screen.

Individual investors have a true advantage over a large fund manager in that most funds will have withdrawals when the market is down and investors are frightened,  and they will get untimely deposits when the market is up. They are often forced to buy high and sell low. Individuals are not forced to but or sell, nor are they held to maximum percentage cash restrictions.  They are also more nimble. With all the money flowing into the sector, investing in a retail size block compared to an institutional size block gives you more pricing power than the big guys.

 

Take-Away

Let the buyer beware especially applies to ESG funds today. There are companies that are reinventing themselves as green that may not fit other definitions, and there are fund managers that are being inundated with cash looking for value in with large trades.

Investors can use their free online trading, and free top-tier research and data from Channelchek and other sources to evaluate companies themselves and weigh them against their own heart.

Paul Hoffman

Managing Editor, Channelchek

 

Capstone Green Energy Corporation (CGRN) Monday June 28 @ 1:00pm EDT

Join Capstone Green Energy Corporation CEO Darren Jamison for this exclusive corporate presentation, followed by a Q & A session moderated by Michael Heim, Noble’s senior research analyst, featuring questions taken from the audience. Registration is free and open to all investors, at any level.

Register Now  |  View All Upcoming Road Shows

 

Suggested Reading:

Who Benefits from the American Jobs Plan?

Big Tech Doing Whatever it Takes to Demonstrate Commitment to Green Solutions



Copper Facing an Onslaught of Demand

Is ESG and B-Corp Investing Smart?

 

Sources:

https://www.cnbc.com/2021/02/11/sustainable-investment-funds-more-than-doubled-in-2020-.html

https:/www.morningstar.com/lp/sustainable-funds-landscape-report

https://www.tiaa.org/public/about-tiaa/news-press/press-releases/pressrelease604.html#:~:text=TIAA%2DCREF%20was%20one%20of,Social%20Choice%20Account%20in%201990

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

What Makes a Country a Tax Haven?

Posted on by Admin 

Image Credit: Reji (Flickr)


What are Tax Havens? The Answer Explains Why the G-7 Effort to end Them is Unlikely to Succeed

 

Close your eyes and imagine a tax haven. Does a Caribbean island come to mind? Sand, surf and thousands of post office boxes housing shell corporations?

Some tax havens, like the Cayman Islands or Bermuda, fit that description. Many others do not.

The key to a tax haven is the taxes, not the tan. Any place that allows a taxpayer – whether an individual or a company – to get a lower tax bill overseas than at home is a tax haven. Thus, depending on the taxpayer’s jurisdiction and business, many places turn out to be tax havens, even the United States.

A recent agreement by the Group of Seven wealthy nations seeks to eliminate corporate tax havens by imposing a global 15% minimum corporate tax rate. However, as a tax expert, I find the effort hard to take seriously.

Put simply, tax havens are jurisdictions that offer low or even no taxes in a bid to attract foreign investment.

From a taxpayer’s perspective, the first sign of a good tax haven is that it’s completely legal. While there may be a perception that people who use tax havens to lower their tax bills are breaking the law, that’s rarely the case.

A taxpayer who is comfortable doing that does not need a tax haven. Instead, a dishonest accountant and a less honest banker are all that’s required.

The second sign of a good tax haven is transparency, political stability and rule of law. If it costs more in lawyers, accountants and bribes to avoid taxes overseas than it costs to pay the tax at home, there is no point to a tax haven.

The third sign is privacy. For many years, Swiss banks provided the gold standard in that regard by refusing to reveal anything about their depositors to anyone. That changed in 2008, when Swiss banks agreed to report on their depositors to 43 European countries.

The loss of the complete secrecy that Switzerland once provided has made shell companies – and the countries that make them easy to set up – much more attractive. Shell companies are basically companies without active business operations or significant assets that are stacked one on top of the other to make it harder to trace ownership.

 

 

In the Eye of the Beholder

Identifying a tax haven isn’t as simple for the government’s intent on controlling them as it is for the taxpayers who seek them out. This is mainly because governments and international organizations tend to think a tax haven is somewhere other than where they live.

For example, the European Union produces an annual list of tax havens that contains no EU member countries, even though many other lists identify Ireland, Luxembourg, and a host of other European countries as tax havens.

And while several groups have described the United States as a tax haven – Forbes even calls it the best in the world – the U.S. government would never do so, even though it fits all the key criteria, such as providing legal ways to avoid virtually all taxation and strong taxpayer privacy.

The Race to the Bottom

This is why the G-7 global corporate minimum 15% tax agreement is unlikely to work.

Of course, I applaud the effort. Without a minimum tax, countries are stuck in a never-ending race to the bottom, whereby every time one government cuts its corporate tax rates, another soon follows with even lower rates.

The problem is the G-7 has to get more than 130 other countries to go along with its minimum tax rate. Many countries, including Ireland and China, seem unlikely to give up something that has brought them so much economic advantage.

 

This article was republished with permission from The
Conversation, a news
site dedicated to sharing ideas from academic experts.  It was written by
and represents the research-based findings and opinion of  Beverly Moran, Professor Emerita of Law, Vanderbilt University

 

Suggested Reading:

No-Cost Brokers Like Robinhood Could be the Big Winners With Rising Rates

Can Brokers Level the Playing Field for Individual Investors?



Is Zero Trust Architecture Enough?

Important Russell Reset Data 2021

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Comstock Mining (LODE) – Comstock Strategy Takes a Quantum Leap

Posted on by Admin

Monday, June 28, 2021

Comstock Mining (LODE)
Comstock Strategy Takes a Quantum Leap

Comstock Mining Inc. is an emerging innovator and leader in the sustainable extraction, valorization, and production of scarce natural resources, with a focus on high value strategic materials that are essential to meeting the rapidly increasing global demand for clean energy, carbon-neutrality, and natural products.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    GenMat investment. Comstock Mining has agreed to purchase an additional 5% of its 45%-owned technology development partner, Quantum Generative Materials LLC (GenMat), for $50 million. Comstock has been working with GenMat for roughly 6 months and executed a transaction in June that provided founders equity for its work and committed it to funding the first phase of a two-year plan. Comstock will provide an initial $15 million in the form $5 million in cash and 3 million shares over the next six months, and an additional $35 million upon GenMat achieving key development milestones. Mr. Corrado De Gasperis, Executive Chairman and CEO of Comstock Mining, is expected to chair GenMat’s board of directors that will include GenMat’s three founders and three Comstock representatives.

    Application across business lines.  GenMat is developing a proprietary quantum operating system for use in various applications. Comstock is focused on applications that accelerate development of new clean technologies. Comstock has secured exclusive rights to use GenMat’s quantum technologies and, for example, intends to use GenMat’s platform to enhance its extraction and refining of lithium and …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Virtual Roadshow with Comstock Mining (LODE) CEO Corrado De Gasperis

Posted on by Admin

Comstock Mining CEO Corrado De Gasperis makes a formal corporate presentation. Afterwards, he is joined by Noble Capital Markets Senior Research Analyst Mark Reichman for a Q & A session featuring questions asked by the live audience throughout the event.

Research, News, and Advanced Market Data on LODE


Information on upcoming live virtual roadshows

About Comstock Mining Inc.

Comstock (NYSE: LODE) is an emerging leader in the sustainable extraction, valorization, and production of innovation-based, clean, renewable natural resources, with a focus on high-value, cash-generating, strategic materials that are essential to meeting the rapidly increasing global demand for clean energy, carbon-neutrality, and natural products. To learn more, please visit www.comstockmining.com. Comstock is also set to join the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, according to a preliminary list of additions posted June 4, 2021. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Release – Onconova Therapeutics Provides An Update On The Phase 1 2a Trial Of Rigosertib-Nivolumab Combination

Posted on by Admin


Onconova Therapeutics Provides An Update On The Phase 1/2a Trial Of Rigosertib-Nivolumab Combination In KRAS+ Non-Small Cell Lung Cancer

 

Expansion of trial underway at highest dose in the current protocol, and continued dose escalation under consideration

Preliminary data support the preclinical observation of rigosertib augmenting the response to immune checkpoint inhibition

NEWTOWN, Pa., June 28, 2021 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced an update on the investigator-initiated Phase 1/2a trial of oral rigosertib plus nivolumab in advanced metastatic KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC). The clinical data to date provide preliminary evidence of potential anti-cancer activity of rigosertib-nivolumab combination therapy in advanced metastatic KRAS+ non-small cell lung cancer and show that the maximum tolerated dose of rigosertib in combination with nivolumab was not reached in the three cohorts of the trial’s dose-escalation phase. Patients enrolled in this trial have failed multiple lines of prior therapy and all have failed immune checkpoint inhibitors in various combinations.

The trial continues to recruit patients as part of the expansion phase at the highest dose of oral rigosertib defined in the current protocol. Based on the positive preliminary findings from the trial, a protocol amendment is being prepared that would allow for the evaluation of increased rigosertib doses in combination with the full dose of intravenous nivolumab, as recommended per its product label.

“The preliminary results from this Phase 1/2a trial are very encouraging and demonstrate the potential of rigosertib to address a critical unmet medical need by overcoming checkpoint inhibitor resistance in KRAS mutated lung adenocarcinoma,” said Mark S. Gelder, M.D., Chief Medical Officer of Onconova. “The observation of preliminary evidence of efficacy in combination with acceptable safety of the doublet in this extremely challenging patient population provides a promising signal. This phase 1 study supports the preclinical observation in melanoma of the up regulation of crucial cell surface molecules by rigosertib which may synergize with immune checkpoint blockade, as recently published in Molecular Cancer, and strongly supports the continued clinical development of rigosertib-checkpoint inhibitor combination therapy. We look forward to the presentation of preliminary data at the upcoming 3rd Annual RAS Targeted Drug Development Summit taking place September 21-23, 2021, and at a future major medical meeting as the data mature.”

Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, commented, “This Phase 1/2a trial is an important part of our investigator-initiated study program, which enables us to pursue opportunities to develop rigosertib in high-need KRAS mutated indications while maintaining our primary focus on our lead ON 123300 program. We are very pleased both with the safety and preliminary efficacy signal we have seen from the KRAS mutated NSCLC trial to date, considering the multiple lines of therapy many of these patients have previously failed, including checkpoint inhibitors in various combinations. We are supportive of the plan to expand dose-escalation of rigosertib to determine the optimal recommended Phase 2 dose of the combination; and are eagerly anticipating results of important correlative science that is part of the trial. We look forward to the trial’s continued progress and would like to thank the investigator and his team for conducting the trial, as well as the patients who are participating.”

About the Investigator-initiated Phase 1/2a Trial
This Phase 1/2a trial is designed to evaluate the combination of rigosertib and nivolumab in advanced KRAS+ metastatic lung adenocarcinoma patients who have progressed on standard of care with anti-PD-1 monotherapy or anti-PD-1 in combination with chemotherapy. It includes a dose-escalating Phase 1 portion followed by a Phase 2a dose-expansion portion. Patients in the trial receive oral rigosertib twice daily on days 1-21, and intravenous nivolumab on days 1 and 15 of 28-day cycles. The primary endpoints of the trial are safety assessments and overall response rate. Secondary endpoints include progression free survival and overall survival. For more information on the trial, see ClinicalTrials.gov Identifier: NCT04263090.

About Onconova Therapeutics, Inc.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, including in a dose-escalation and expansion Phase 1/2a investigator-initiated study targeting patients with KRAS+ non-small cell lung cancer with oral rigosertib in combination with nivolumab. In addition, Onconova continues to conduct preclinical work investigating rigosertib in COVID-19.

For more information, please visit www.onconova.com.

Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the timing of Onconova’s and investigator-initiated clinical development and data presentation plans, and the mechanisms and indications for Onconova’s product candidates. Onconova has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova’s clinical trials, investigator-initiated trials and regulatory agency and institutional review board approvals of protocols, Onconova’s collaborations, the timing of the Company’s annual stockholder meeting, market conditions and those discussed under the heading “Risk Factors” in Onconova’s most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
[email protected]
https://www.onconova.com/contact/

Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
[email protected]

Release – Kratos Successfully Completes Engine Testing for an Affordable and High Performance Turbine Engine

Posted on by Admin


Kratos Successfully Completes Engine Testing for an Affordable and High Performance Turbine Engine for Future Expendable Cruise Missiles and Attritable UAVs

 

SAN DIEGO, 
June 28, 2021 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS) announced today that Kratos Turbine Technologies (KTT) Division has successfully completed a core engine test campaign under KTT’s Advanced Turbine Technologies for 
Affordable Mission (ATTAM) contract. This turbine engine development program is managed by the Turbine Engine Division of the 
Air Force Research Laboratory (AFRL/RQT). Testing of the engine core supports the development of small, affordable, high-performance jet engines for cruise missiles and Unmanned Aerial Vehicles (UAVs). During the test campaign, KTT successfully demonstrated key performance and operability targets of the core engine.

Stacey Rock, President of Kratos Turbine Technologies Division, said, “The successful core engine test demonstrates the great working relationship that KTT has with the AFRL Turbine Engine Division, and the desire from both parties to increase capability and lower cost of expendable turbine engine propulsion. We look forward to continuing to support AFRL in the development of transformative and affordable turbine engine technologies. All of Kratos is focused on supporting 
the United States warfighter and industrial base, including making significant investments in the development and production of next generation engines and supporting STEM opportunities in the USA.”

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended 
December 27, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the 
SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687
[email protected]

Source: Kratos Defense & Security Solutions, Inc.

Release – Cocrystal Joins Russell Microcap Index

Posted on by Admin


Cocrystal Joins Russell Microcap® Index

 

BOTHELL, Wash., June 28, 2021 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces that it will be added to the Russell Microcap® Index after the U.S. market opens today, June 28, 2021.

“We are delighted that Cocrystal will now be included in the Russell Microcap® Index, which is a broadly used performance benchmark for smaller growth stocks in the U.S.,” said James Martin, Cocrystal’s interim co-CEO and CFO. “This is a notable milestone for Cocrystal that will further raise awareness of our company within the global investment community as we advance development of our antiviral programs including the planned initiation of an influenza A Phase 1 trial in the third quarter.”

Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell a leading global index provider determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s U.S. indexes. For more information on the Russell Microcap Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website. The information on the FTSE Russell website is not part of this press release.

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of coronaviruses (including SARS-CoV-2), influenza viruses, hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the advancement of our programs such as the planned initiation of influenza A Phase 1 trial in the third quarter of 2021. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from the impact of the COVID-19 pandemic on the national and global economy and on our Company, including supply chain disruptions and our continued ability to proceed with our programs, including our influenza A program, our ability to complete the preclinical and clinical trials, the ability of the contract research organization to recruit subjects, the results of such future preclinical and clinical studies, and general risks arising from clinical trials and more generally, the development of investigational drugs. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
[email protected]

Source: Cocrystal Pharma, Inc.

Release – Capstone Green Energy Secures Order For Multiple Microturbines For Australian Oil And Gas Customer

Posted on by Admin

 


Capstone Green Energy Secures Order For Multiple Microturbines For Australian Oil & Gas Customer

 

VAN NUYS, CA / ACCESSWIRE / June 28, 2021 / Capstone Green Energy Corporation (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) formerly Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST) (“Capstone” or the “Company”), a global leader in carbon reduction and on-site resilient green energy solutions, announced today it would be providing two C600S microturbine systems and one C800S microturbine system in support of several oil and gas projects in Australia. All three systems are expected to be delivered between June to December 2021. The order, secured by Capstone’s Australian distributor, Optimal Group, aims to provide the customer with greater energy efficiency, reduced emissions, and increased power security.

The units will be installed at multiple locations and will use high-pressure natural gas. The dual-mode turbines will be operating in a standalone configuration, supplying all of the site’s electrical demand. Capstone’s Power Sync Master Controller, which supports on-site controls and integration with the end-use customer’s facilities, further increases the reliability and availability of the C600S and C800S systems through its unique “self-healing” Ethernet ring, which eliminates single points of failure in its control network.

Facing growing pressure to address climate change, oil and gas companies are pledging to prepare for a low-carbon or “lower-carbon” future. For many, that involves investing in new technologies and infrastructure that can support new, greener ways of generating electricity. These are the key areas in which Capstone Green Energy has built its business and where it continues to innovate.

“For many years, Capstone has been an innovative energy partner to the oil and gas industry,” said Darren Jamison, President and Chief Executive Officer of Capstone Green Energy. “As the oil and gas industry moves toward a more environmentally-friendly future, we are providing solutions that go beyond emissions reduction, often strengthening power reliability and improving the bottom line,” added Mr. Jamison.

“We are increasingly finding that customers who need reliable power to operate remote and off-grid facilities are recognizing the inherent benefits of Capstone’s unique microturbine-based energy solutions,” said Kane Ravenscroft, Sales Director for Optimal Group. “The modularity built into Capstone’s C600S and C800S systems, with multiple, independent turbine modules in a single package, provides the availability and uptime that these customers need to maintain production. Coupling this with the ability of each turbine to operate from a zero load to 100% load, or switch off, based on changing site demands, delivers the load control, emissions reductions and optimal efficiency mix that is not available with other technologies,” concluded Mr. Ravenscroft.

About Capstone Green Energy

Capstone Green Energy (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) is a leading provider of customized microgrid solutions and on-site energy technology systems focused on helping customers around the globe meet their environmental, energy savings, and resiliency goals. Capstone Green Energy focuses on four key business lines. Through its Energy as a Service (EaaS) business, it offers rental solutions utilizing its microturbine energy systems and battery storage systems, comprehensive Factory Protection Plan (FPP) service contracts that guarantee life-cycle costs, as well as aftermarket parts. Energy Conversion Products are driven by the Company’s industry-leading, highly efficient, low-emission, resilient microturbine energy systems offering scalable solutions in addition to a broad range of customer-tailored solutions, including hybrid energy systems and larger frame industrial turbines. The Energy Storage Products business line designs and installs microgrid storage systems creating customized solutions using a combination of battery technologies and monitoring software. Through Hydrogen Energy Solutions, Capstone Green Energy offers customers a variety of hydrogen products, including the Company’s microturbine energy systems.

For customers with limited capital or short-term needs, Capstone offers rental systems; for more information, contact: [email protected]. To date, Capstone has shipped over 10,000 units to 83 countries and estimates that, in FY21, it saved customers over $217 million in annual energy costs and approximately 397,000 tons of carbon. Total savings over the last three years are estimated at 1,115,100 tons of carbon and $698 million in annual energy savings.

For more information about the Company, please visit: www.CapstoneGreenEnergy.com. Follow Capstone Green Energy on Twitter, LinkedIn, Instagram, Facebook, and YouTube.

Cautionary Note Regarding Forward-Looking Statements

This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding expectations for green initiatives and execution on the Company’s growth strategy and other statements regarding the Company’s expectations, beliefs, plans, intentions, and strategies. The Company has tried to identify these forward-looking statements by using words such as “expect,” “anticipate,” “believe,” “could,” “should,” “estimate,” “intend,” “may,” “will,” “plan,” “goal” and similar terms and phrases, but such words, terms and phrases are not the exclusive means of identifying such statements. Actual results, performance and achievements could differ materially from those expressed in, or implied by, these forward-looking statements due to a variety of risks, uncertainties and other factors, including, but not limited to, the following: the ongoing effects of the COVID-19 pandemic; the availability of credit and compliance with the agreements governing the Company’s indebtedness; the Company’s ability to develop new products and enhance existing products; product quality issues, including the adequacy of reserves therefor and warranty cost exposure; intense competition; financial performance of the oil and natural gas industry and other general business, industry and economic conditions; the Company’s ability to adequately protect its intellectual property rights; and the impact of pending or threatened litigation. For a detailed discussion of factors that could affect the Company’s future operating results, please see the Company’s filings with the Securities and Exchange Commission, including the disclosures under “Risk Factors” in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

CONTACT:
Capstone Green Energy
Investor and investment media inquiries:
818-407-3628
[email protected]

SOURCE: Capstone Green Energy Corporation